Best Amazon Prime Day deals in Canada 2025
CONSUMABLES
Article content
Whitening strips: Crest 3D White Whitestrips Professional Effects (Now: $45 | Was: $66.50) Toothbrush: Philips Sonicare Diamondclean Toothbrush (Now: $135 | Was: $250) Toothbrush: Oral-B iO Series 7L Electric Toothbrush (Now: $185 | Was: $300) Water flosser: Waterpik Cordless 2.0 Water Flosser for Teeth (Now: $80 | Was: $136) Eye mask: grace & stella Under Eye Mask (Now: $19 | Was: $40) Throat spray: Beekeeper's Naturals Propolis Throat Spray (Now: $12 | Was: $17)
Eye drops: Biotrue Preservative Free Eye Drops (Now: $10.50 | Was: $15)
Hair removal cream: VEET Hair Removal Cream (Now: $13 | Was: $20) Medicated patches: Icy Hot Medicated Pain Patch (Now: $9 | Was: $12.50)
Melatonin supplements: OLLY Ultra Strength Sleep Softgels (Now: $18 | Was: $27)
Probiotics: Jamieson Probiotic 60 Billion 24 Capsules (Now: $19 | Was: $33)
Fibre supplement: Metamucil, Daily Psyllium Husk Powder (Now: $21 | Was: $29) Vitamin D3 supplement: GNA Naturals Vitamin D3 Drops (Now: $15 | Was: $20) Tylenol: Extra Strength Tylenol (Now: $10 | Was: $18)
Cold medicine: Mucinex Multi-Action Cold & Flu Caplets (Now: $10 | Was: $15)
Antinausea: Gravol Ginger (Now: $7.50 | Was: $10)
Pads: Always Infinity with FlexFoam Pads (Now: $22 | Was: $33.50) Alka-Seltzer: Alka-Seltzer Antacid Heartburn Relief Effervescent Tablets (Now: $7 | Was: $9) Kids vitamins: Jamieson Multivitamin Gummies for Kids (Now: $14 | Was: $19)
Article content
Article content
FASHION
Article content
BEAUTY
Article content
KIDS & BABY
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
16 minutes ago
- Globe and Mail
Ibogaine by David Dardashti Warns of Kratom's ‘Gateway' Dangers, Citing Alarming Trend in Patient Addiction Cases
WESTCHESTER, FL - August 4, 2025 - As the FDA intensifies its crackdown on the potent kratom compound 7-hydroxymitragynine (7-OH), the addiction treatment center Ibogaine by David Dardashti is issuing a critical warning based on alarming clinical trends. The clinic's founder, David Dardashti, is speaking out about the substance's deceptive role as a gateway to more dangerous opioids, based on a sharp increase in patients seeking treatment for kratom dependency at his facility. The recent FDA actions targeting concentrated 7-OH products—dubbed 'legal morphine' by some researchers—underscore a danger the clinical team at Ibogaine by David Dardashti sees daily. The clinic has witnessed a significant increase in patients arriving with a primary or secondary addiction to kratom, often after being misled by marketing that promotes it as a safe, herbal alternative to opioids. This firsthand clinical data forms the basis for their urgent public warning. 'We are seeing a disturbing pattern,' states David Dardashti. 'Patients come to us after starting with kratom, thinking it's a safe, natural remedy. They don't realize they are developing a true opioid dependency until it's too late. The initial effects fade, tolerance builds, and suddenly they are facing a full-blown addiction with severe withdrawals. The next logical step for many is to seek out something stronger and deadlier, like fentanyl. We are on the front lines of this trend, and it is alarming.' As referenced in recent reports, experts confirm that while the kratom leaf itself may be mild, concentrated extracts containing 7-OH are significantly more potent and act as pure opioids. This creates the dangerous cycle of dependency that the clinic observes. Users require ever-increasing doses, eventually finding that the legal substance no longer satisfies the addiction it created, driving them toward the illicit drug market. Despite the alarming trend, the team at Ibogaine by David Dardashti reports significant success in treating kratom addiction and offers a message of hope. Based on extensive clinical experience, the center has found a notable distinction in the recovery process for these patients. 'The good news in this growing crisis is that we've found that individuals dependent on kratom can be brought back to sobriety with less difficulty than those entrenched in long-term Suboxone or fentanyl use,' Dardashti explains. 'Ibogaine therapy works to reset the brain's neurotransmitters and interrupt addiction at the source. For our kratom patients, the process is often smoother and the path to a full recovery is remarkably clear. Our goal is to intervene effectively before the addiction escalates into a far more tragic story.' About Ibogaine by David Dardashti: Ibogaine by David Dardashti is a leading treatment center dedicated to helping individuals overcome chemical dependency through a unique combination of ibogaine therapy and holistic care. Founded by David Dardashti, the clinic leverages extensive clinical experience to provide a safe, medically supervised environment for profound psycho-spiritual healing and neurological reset, offering a definitive interruption to the cycle of addiction.
National Post
2 hours ago
- National Post
PetPace Responds to Whistle Shutdown with Exclusive Offer on PetPace Collar as a Smarter Solution for Health, Wellbeing and GPS Tracking
$80 Off + Free Month with One-Year Subscription for Verified Whistle Users Article content BURLINGTON, Mass. — PetPace announced today that, following the acquisition of Whistle and the confirmation that all Whistle smart collars will be shut down by August 31, 2025, many pet owners are now facing the challenge of finding a reliable solution to continue monitoring their pets' location and health. In response, PetPace is extending an unprecedented opportunity to Whistle pet parents, inviting them to transition to the PetPace smart collar—an advanced GPS and AI health monitoring device that significantly surpasses basic activity trackers in both features and data insights. Article content Unlike traditional collars that focus primarily on activity, PetPace offers a clinically validated health tracking platform with a broader scope of data, including vital signs, behavior trends, and early indicators of health issues. Whistle users are encouraged to explore this limited time offer and experience the enhanced peace of mind that comes with a truly comprehensive pet health and safety solution. Article content 'In the wake of the acquisition of Whistle, a major disruption is underway in the pet tech world: all Whistle smart collars will be deactivated, leaving pet owners to seek out a replacement for health and location tracking tools. PetPace warmly welcomes all whistle customers to experience how a superior and real health monitoring collar can provide AI predictive healthcare monitoring with vet/patient connectivity,' said Avner Schneur, Cofounder and Chairman of the Board. As a friendly and empathetic gesture to Whistle pet parents looking for a more advanced, dependable alternative, PetPace is offering our deepest discount yet at $80 off the PetPace collar + your first month free exclusively for verified Whistle collar users. Apply here: PetPace: More Than a GPS and Activity Tracking Collar For those who've come to rely on the location tracking of Whistle, PetPace delivers that and much more. While Whistle collars primarily focused on GPS and basic activity tracking, PetPace takes pet care significantly further by offering a comprehensive suite of health and behavior monitoring tools that were never available on Whistle devices. With PetPace, pet parents gain access to: Article content Live GPS Tracking – Keep your pet safe with accurate, real-time location monitoring comparable to Whistle's core feature. Vital Health Metrics – Unlike Whistle, PetPace continuously monitors key physiological indicators such as heart rate, heart rate variability (HRV), respiration, body temperature, and calorie burn—providing a much deeper understanding of your pet's health. Advanced Behavioral Monitoring – PetPace uses AI to detect patterns in posture, sleep quality, activity levels, and stress—data Whistle users never had access to. Smart Alerts and Predictive Health Insights – Proprietary algorithms analyze the collected data and send early warnings about possible illness or distress, helping you intervene before a condition worsens. Veterinary Integration – PetPace offers the option to share health data directly with your veterinarian for faster, more informed care—something not supported by Whistle. Proven, Research-Based Technology – Used in veterinary hospitals, clinical studies, and academic research settings around the world, PetPace is a medically trusted solution, not just a consumer gadget. Built to Last – With no planned obsolescence or forced shutdowns, PetPace is a long-term investment in your pet's wellbeing Article content Article content Whether you're coming from Whistle or just beginning your search for better pet care tools, PetPace offers a unique combination of technology, reliability, and peace of mind that's in a class of its own. How to Redeem the Offer: Article content Offer valid through September 15, 2025, or while supplies last. Article content About PetPace Article content PetPace, based in Burlington, MA, is the leading provider of the most advanced, award-winning technology in holistic pet health solutions. Designed by vets for home use, the PetPace collar is dedicated to enhancing pet wellness through the world's most advanced wearable technology. Our patented AI/ML-powered smart collar continuously collects near real-time physiological and behavioral data, enabling early detection of health issues and redefining predictive pet care. Composed of veterinarians, IoT professionals, engineers, AI experts, and data specialists, our team collaborates with top universities and research institutes worldwide. Trusted by veterinarians, researchers, and pet owners, PetPace is dedicated to protecting and improving pet health. For more information visit: Article content Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Margie Adelman Article content Article content Article content
Globe and Mail
2 hours ago
- Globe and Mail
J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
Johnson & Johnson JNJ announced strong second-quarter results earlier this month. The drug and medical device giant beat estimates for both earnings and sales. Despite the loss of exclusivity ('LOE') of its blockbuster drug, Stelara, its Innovative Medicine unit once again outperformed expectations, with sales of all key drugs Darzalex, Erleada and Tremfya beating estimates. The new drugs also contributed significantly to sales. Importantly, its MedTech sales improved from first-quarter levels, driven by strong momentum in Cardiovascular, Surgery and Vision segments despite continued headwinds in China. But what caught investor attention is the fact that J&J raised its sales expectations for 2025 by around $2.0 billion at the mid-point to reflect a strong operational performance in the first half, coupled with currency tailwinds. The sales guidance was raised from a range of $91.0 billion-$91.8 billion to $93.2 billion-$93.4 billion. The sales range indicates growth in the range of 5.1%-5.6% versus the prior expectation of 2.6%-3.6%. The adjusted earnings per share guidance was raised from a range of $10.50-$10.70 to $10.80-$10.90, driven by top-line strength, the favorable impact of foreign currency and lowered tariff impact. J&J halved its expectations for tariff-related costs this year from $400 million to $200 million. J&J expects operational sales growth in both the Innovative Medicine and MedTech segments to be higher in the second half than in the first. Newly launched products should drive better growth in the Innovative Medicine segment in the second half despite the impact of Stelara LOE and Medicare Part D redesign. The growth is expected to be driven by its key products, such as Darzalex, Tremfya, Spravato and Erleada as well as new drugs like Carvykti, Tecvayli and Talvey and new indications, including Tremfya in inflammatory bowel disease indications and Rybrevant in non-small cell lung cancer. In the MedTech segment, the increased adoption of newly launched products in Cardiovascular, Surgery and Vision is likely to drive growth. However, China will continue to be a headwind in 2025. Sales are expected to be higher in the second half than the first half as the business moves past tougher first-half comps and new products gain momentum throughout 2025. We believe that J&J should be able to maintain the strong momentum of the first half in the second half. In fact, J&J expects growth to accelerate from 2026. ABBV & BMY Also Raise Guidance Other drugmakers that also raised their financial outlook for the year, along with their second-quarter results, are AbbVie ABBV and Bristol-Myers BMY. ABBV raised its full-year 2025 EPS guidance to $11.88-$12.08, up from its prior $11.67-$11.87 range.' Bristol-Myers raised its annual revenue guidance to $46.5-$47.5 billion from $45.8-$46.8 billion. BMY, however, cut its EPS outlook due to IPRD charges related to its recent deal with BioNTech BNTX for the global co-development and co-commercialization of BNTX's investigational bispecific antibody BNT327 across numerous solid tumor types. JNJ's Price Performance, Valuation and Estimates J&J's shares have outperformed the industry year to date. The stock has risen 17.6% in the year-to-date period against a 3.3% decrease of the industry. Image Source: Zacks Investment Research From a valuation standpoint, J&J is slightly expensive. Going by the price/earnings ratio, the company's shares currently trade at 15.0 forward earnings, slightly higher than 14.29 for the industry. The stock is, however, trading below its five-year mean of 15.68. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 earnings has risen from $10.62 per share to $10.86 over the past 30 days, while that for 2026 has risen from $11.0 to $11.36 over the same timeframe. Image Source: Zacks Investment Research J&J has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
